Shanghai Fosun Pharmaceutical (Group) Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Shanghai Fosun Pharmaceutical (Group) Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 10 Jun 2021 | Lorem |
| China’s new regulations set stage for greater partnerships and acquisitions between Chinese and international pharma, CROs – experts | 29 Nov 2017 | Fiona Barry, Shuan Sim, Alaric DeArment |
| Western CAR-T companies pursuing China will face IP hurdles, but may gain branding edge – experts | 17 Feb 2017 | Alaric DeArment |
| CAR-T pursuits in China face pricing headache for broad coverage, likely restriction to urban regions – experts | 16 Feb 2017 | Alaric DeArment |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer